NCT00796354已完成3 期
A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® With Placebo in Patients With Constipation Associated With Irritable Bowel Syndrome (IBS)
Norgine21 个研究点 分布在 7 个国家目标入组 210 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
- 试验地点
- 21
- 主要终点
- To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.
研究概览
简要总结
Multi-centre, double-blind, randomised, placebo-controlled, parallel group study.
详细描述
Patients will be treated for 28 days, with clinical assessments carried out over 2 visits. Follow-up will be performed via telephone at a specific interval during the study to determine the outcome of unresolved AEs, any new drug-related AEs or any pregnancies. During the run-in period and the treatment phase, patients are prohibited from taking prescription or over the counter (OTC) laxative medication or constipating medications. Prescription and OTC medications not related to constipation are permitted and must be fully documented, but any changes (e.g., dosage, regimen) are to be limited as much as possible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and females aged 18 to 80 years inclusive.
- •Written informed consent obtained.
- •Females of child-bearing potential must employ an adequate method of contraception and must undergo a pregnancy test at Randomisation Visit.
- •Willing, able and competent to complete the entire study and comply with study instructions.
- •Patients > 50 years old have to have undergone a colonoscopy or computerised tomography (CT) after the onset of their IBS-C symptoms or within the last 5 years.
- •Patient has diagnosed IBS-C using Rome III criteria for the last 3 months, with symptom onset at least 6 months prior to diagnosis.
排除标准
- •History or evidence of organic disease in the large bowel, intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, complicated diverticulitis, ulcerative colitis, toxic megacolon and occlusive or subocclusive syndrome.
- •Abdominal pain of unknown cause, not related to IBS.
- •Previous major abdominal surgery.
- •IBS subtype other than IBS-C.
- •Known allergy to polyethylene glycol (PEG) 3350 or known hypersensitivity to any of the active substances.
- •Laxative, drug or alcohol abuse (recent history or within previous 12 months).
- •Pregnant or lactating females.
- •Severe or acute disease within 2 weeks prior to the start of the study.
- •Patients with type I or II diabetes.
- •Use of other investigational drugs, prescribed or OTC medications affecting gastrointestinal function such as anticholinergics, prokinetics, drugs affecting motility, anthraquinones, opioids,ondansetron or other 5-HT3 antagonists.
- •Incomplete Patient Diary Card during the run-in period.
- •The occurrence of diarrhoea* during the run-in period.
- •Patients with abnormal laboratory tests, proctoscopy /abdominal ultrasound, colonoscopy, sigmoidoscopy or CT that requires further investigation.
- •Patients with any condition, which, in the Investigator's may put the patient at significant risk, may confound the study results, or may interfere significantly with the results of the study.
- •Participation in another clinical study of drugs or devices parallel to or less than 1 month before study entry, or previous participation in this study.
- •Employees of the Investigator or study site with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator.
研究组 & 干预措施
NRL920
Active Comparator
干预措施: MOVICOL (Drug)
Placebo
Placebo Comparator
干预措施: Sugar Pill (Drug)
结局指标
主要结局
To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.
时间窗: April 2009
次要结局
- To evaluate the effect of treatment on other symptoms of IBS.(April 2009)
- To evaluate the effect of treatment on patient's Quality Of Life (QOL).(April 2009)
研究者
研究点 (21)
Loading locations...
相似试验
已完成
3 期
Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal EndoscopySedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic PolypectomyNCT01961349AstraZeneca279
终止
3 期
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis BronchiectasisNon-cystic Fibrosis BronchiectasisNCT05006573AstraZeneca100
进行中（未招募）
3 期
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Multiple SclerosisNCT04544436Hoffmann-La Roche864
已完成
3 期
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)COVID-19NCT05084911Shin Poong Pharmaceutical Co. Ltd.1,807
终止
3 期
A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)Systemic Lupus ErythematosusLupus NephritisNCT00626197Genentech, Inc.381